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Abstract 
Lung cancer is the leading cause of cancer mortality in the United States for both men and 
women.  Lung cancer screening with low-dose computed tomography (LDCT) demonstrates 
reductions in lung cancer mortality and all-cause mortality, and improved rates of early stage 
diagnosis in high-risk current and former adult smokers.  Evidence-based screening guidelines 
include annual LDCT in high-risk current and former adult smokers; however, these guidelines 
have not been fully translated into clinical practice.  The purpose of this project was to create a 
toolkit for lung cancer screening to assist primary care providers in educating and screening their 
patients at high-risk for lung cancer with an overall goal of reducing lung cancer mortality and 
improving early stage diagnosis of lung cancer.  An educational intervention using single group 
post-test was carried out in a primary care practice.  Providers were asked to use a toolkit that 
included resources for lung cancer screening in clinical practice.  Survey data was collected to 
determine effectiveness of the toolkit and educational intervention.  Analysis of the data 
indicated that the toolkit may be beneficial to practice, although there were provider concerns 
about time and patient receptiveness.  Lung cancer is a significant cause of mortality; giving 
providers tools to educate and screen high-risk patients for lung cancer may reduce mortality 
rates and improve survival. 
Keywords: computed tomography, decision aid, education, high-risk adult smokers, low-
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An Educational Toolkit to Promote Lung Cancer Screening in Primary Care  
Introduction 
 Lung cancer is the number one cause of cancer death in the United States despite a steady 
reduction in lung cancer mortality rates since 1990 (American Cancer Society [ACS], 2016a; 
Boiselle, 2013; Manser et al., 2013; Moyer, 2014).  When diagnosed at stage I, five-year survival 
rates range from 45% to 49% (ACS, 2016a).  Seventy-nine percent of lung cancers are diagnosed 
when cancer has already metastasized to lymph nodes or distant areas, and survival rates are 
significantly reduced (ACS, 2016a; Bach et al., 2012; Surveillance, Epidemiology, and End 
Results Program [SEER], 2016; Wender et al., 2013).  In 2010, the National Lung Screening 
Trial Research Team (2011) released results from their large randomized controlled trial (RCT) 
showing a significant reduction in lung cancer mortality rates with annual low-dose computed 
tomography (LDCT) in high-risk current and former adult smokers.  Based on these results, the 
ACS and the United States Preventive Service Task Force (USPSTF) released guidelines in 2013 
recommending annual LDCT for lung cancer screening in adults with a significant history of 
smoking.  The purpose of this Doctor of Nursing Practice (DNP) project was to create a toolkit 
for lung cancer screening to assist primary care providers in educating and screening their 
patients at high-risk for lung cancer, with an overall goal of reducing lung cancer mortality and 
improving rates of early stage diagnosis of lung cancer. 
Evidence of the Problem 
In both men and women, lung cancer is the leading cause of cancer death, accounting for 
approximately 25% of cancer mortality (ACS, 2016a).  In 2013 in the United States, 212,584 
individuals were diagnosed with lung cancer while 156,176 individuals died from lung cancer 
(Division of Cancer Prevention and Control, 2016).  Estimates for 2017 predict 222,500 new 
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cases of lung cancer and 155,870 deaths from lung cancer (ACS, 2017).  As the statistics 
demonstrate, lung cancer is prevalent in the United States and is a significant cause of mortality.  
Even when diagnosed early at stage I, non-small cell lung cancer (NSCLC) has a five-year 
survival rate of 45% to 49%, whereas stage I small cell lung cancer (SCLC) has a five-year 
survival rate of 31% (ACS, 2016a; ACS, 2016b).  About 57% of lung and bronchus cancers are 
diagnosed after metastasis to distant areas, and the five-year relative survival rate is only 4.2% at 
that stage (SEER, 2016).  About 16% of lung and bronchus cancers are diagnosed at a local site, 
indicating that only 16% will have favorable survival rates (SEER, 2016). 
Smoking is the leading cause of lung cancer and accounts for 80% of deaths from lung 
cancer (ACS, 2016a).  Individuals who currently smoke and those who have quit are both at risk 
as lung cancer develops over approximately 20 years (Manser et al., 2013).  As compared to non-
smokers, individuals who smoke are 15 to 30 times more at risk of developing lung cancer and 
dying from lung cancer (Centers for Disease Control and Prevention, 2015).  Efforts have been 
made toward smoking cessation in various ways such as banning smoking in certain areas, 
discussing smoking cessation with patients, informing the public of its adverse effects, making it 
a national objective, and retail stores not selling tobacco products (Office of Disease Prevention 
and Health Promotion, 2017).  In addition to a history of smoking, the elderly are more likely to 
develop lung cancer; about two of three individuals diagnosed with lung cancer are 65 years of 
age or older, while less than two percent are younger than 45 years of age (ACS, 2016a).  The 
chance of a male developing lung cancer in his lifetime is one in 14, while this chance is one in 
17 for women (ACS, 2016a). 
Beginning in the 1970s and 1980s, studies were conducted to determine if screening with 
chest x-ray (CXR) with or without sputum cytology would reduce lung cancer mortality (Wender 
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et al., 2013).  Four RCTs were conducted with this design and failed to show a statistically 
significant reduction in lung cancer mortality (Wender et al., 2013).  Subsequently, the ACS 
removed its recommendation for lung cancer screening with CXR for current and former 
smokers (Wender et al., 2013).  Further efforts to determine an effective screening method to 
diagnose lung cancer at an earlier stage for high-risk individuals continued (Wender et al, 2013).  
In observational studies, LDCT of the chest was able to identify more lung cancers and nodules 
than chest radiography (The National Lung Screening Trial Research Team, 2011).  Non-
comparative cohort studies with an evaluation of LDCT for lung cancer screening have also been 
conducted. 
RCTs that compared LDCT to CXR with or without sputum cytology and no screening 
have been conducted.  The largest of these trials was the National Lung Screening Trial (NLST), 
where researchers randomly assigned 53,454 current and former adult smokers at high-risk of 
developing lung cancer to receive annual LDCT or CXR (The National Lung Screening Trial 
Research Team, 2011).  In this study, there were 247 deaths from lung cancer per 100,000 
person-years in the LDCT group versus 309 deaths per 100,000 person-years in the CXR group, 
resulting in a relative reduction in lung cancer mortality of 20% with LDCT screening (95% CI, 
6.8-26.7; p = .004); screening with LDCT detected more stage I lung cancers than CXR in this 
study (50% vs. 31.1%, respectively) (The National Lung Screening Trial Research Team, 2011).  
Over the past few years, several organizations, including the ACS and the USPSTF, have 
released guidelines for lung cancer screening that recommend LDCT in a high-risk population of 
current and former adult smokers.  These guidelines are based primarily on the findings of the 
NLST, but findings from other RCTs and cohorts were included in the reviews.  Organizational 
guidelines differ in the criteria utilized to determine which individuals are eligible to be 
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screened.  The American Academy of Family Physicians (AAFP) (2013) does not even support 
LDCT for lung cancer screening; the AAFP believes that the evidence is insufficient to 
recommend for or against screening. 
Several systematic reviews regarding lung cancer screening with LDCT have been 
published (Acikgoz et al., 2014; Bach, Kelley, Tate, & McCrory, 2003; Bach et al., 2012; Bach, 
Silvestri, Hanger, & Jett, 2007; Black et al., 2006; Boiselle, 2013; Humphrey et al., 2013; 
Humphrey, Teutsch, & Johnson, 2004; Manser et al., 2013; Midthun & Jett, 2008; Ravenel, 
Costello, & Silvestri, 2008; Slatore, Sullivan, Pappas, & Humphrey, 2014).  The effectiveness of 
LDCT and its risks versus benefits were evaluated in these reviews.  Although a significant 
reduction in lung cancer mortality was demonstrated in the NLST, other studies did not have 
similar significant findings.  There are also harms with LDCT as a screening technique for lung 
cancer including false-positives, incidental findings, invasive procedures, over-diagnosis, and 
radiation exposure (Wender et al., 2013).  False-positives can lead to additional testing, 
emotional distress, and invasive procedures that may result in a benign finding.  The authors of 
these reviews have concluded that more data is needed to weigh benefits versus risks and 
determine cost-effectiveness of LDCT for lung cancer screening.  As LDCT is recommended in 
high-risk individuals, providers should have a discussion regarding risks versus benefits with 
their patients who are high-risk for developing lung cancer.  Lung cancer screening is also the 
first cancer screening modality that requires documentation of a shared decision-making visit for 
reimbursement by the Centers for Medicare and Medicaid Services (CMS) (Carter-Harris, Tan, 
Salloum, & Young-Wolff, 2016). 
Problem Statement 
Current and former smokers are at an increased risk of developing lung cancer.  This is a 
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significant health problem as prognosis is poor when lung cancer is diagnosed at a late stage.  
LDCT has become a promising screening tool for lung cancer in individuals with a significant 
history of smoking.  Although lung cancer screening guidelines by the ACS and USPSTF were 
released in 2013, it takes time for primary care providers to implement routine screening into 
daily practice.  Mortality from lung cancer among high-risk current and former adult smokers is 
indicated by high lung cancer mortality rates, late stage diagnosis of lung cancer, and lack of 
adherence to lung cancer screening guidelines in primary care.  To address the identified 
problem, a toolkit was created to assist primary care providers in educating and screening their 
patients at high-risk for lung cancer, with an overall goal of reducing lung cancer mortality and 
improving rates of early stage diagnosis of lung cancer. 
Review of the Literature 
 The poor survival rates of lung cancer and the positive findings of LDCT for lung cancer 
screening in the NLST warrants an additional review of the literature to determine benefits 
versus harms.  The literature was searched for publications that included a discussion of the 
effectiveness of LDCT for lung cancer screening.  Cumulative Index of Nursing and Allied 
Health Literature (CINAHL) and Academic Search Premier were searched with the following 
keywords: “computed tomography”, “lung cancer”, and “screening”.  An additional limiter was 
research studies only when searching CINAHL.  Studies published in the English language and 
full text articles that were available through University of Massachusetts Amherst links were 
considered for inclusion in this review; these links allowed access to articles from databases such 
as Cochrane Library, Ovid, PubMed Central, and Science Direct.  Studies published from 
January 01, 2000 to June 11, 2016 were considered for inclusion. 
 Studies that evaluated LDCT for lung cancer screening were considered for inclusion in 
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this integrative review.  Comparators included CXR, sputum cytology, positron emission 
tomography, and no screening.  There were no limitations on the type of setting that the studies 
were conducted in.  RCTs were preferred, but cohort designs were considered if LDCT for lung 
cancer screening was the intervention of choice.  This review considered studies with the 
following outcomes: lung cancer mortality, all-cause mortality, and stage at diagnosis of lung 
cancer.  The highest levels of evidence were sought, and studies were rated using the John 
Hopkins Nursing Evidence-Based Practice (JHNEBP) Model (Dearholt & Dang, 2012). 
 Selected studies were limited to those whose samples included males and females aged 
50 years and older who were current or former smokers with at least a 10 pack-year history of 
smoking.  Large studies with sample sizes of 500 participants and above were included.  It was 
preferred that participants of the studies reviewed had no history of lung cancer or other cancer, 
but studies that included participants with a history of cancer were considered for inclusion. 
Results and Discussion 
 The search yielded 836 articles, which were scanned for inclusion in this integrative 
review.  Of those articles, 42 were thoroughly evaluated to determine if they met inclusion 
criteria.  Nine studies were excluded due to age of participants, seven due to presence of 
nonsmokers in the study population, seven due to outcomes, six due to duplication of studies, 
three due to sample size, and one due to inability to access the full article.  Of the 15 included 
studies, seven were RCTs, and eight were cohort studies.  Of the RCTs, three compared LDCT to 
CXR, while four compared LDCT to no screening.  The NLST was the largest of the trials, 
where 26,722 participants were randomized to the LDCT group and 26,732 participants to the 
CXR group (The National Lung Screening Trial Research Team, 2011).  Gohagan et al. (2005) 
compared LDCT to CXR with 1,660 in the LDCT arm and 1,658 in the CXR arm, while 
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Blanchon et al. (2007) randomized 385 participants to the LDCT arm and 380 participants to the 
CXR arm.  The NLST participants and the Depiscan study participants received a total of three 
scans, while participants in the Lung Screening Study received a total of two scans (Blanchon et 
al., 2007; Gohagan et al., 2005; The National Lung Screening Trial Research Team, 2011).  In 
the remaining four RCTs, the control groups received an annual clinical review only.  Sample 
sizes of these studies varied from 2,450 in the Detection and Screening of Early Lung Cancer 
with Novel Imaging Technology (DANTE) study to 4,104 in the Danish Lung Cancer Screening 
Trial (DLCST) (Infante et al., 2015; Saghir et al., 2012).  Participants in the DANTE trial, the 
DLCST, and the German Lung Cancer Screening Intervention Trial (LUSI) received a total of 
five annual LDCT scans, while participants in the ITALUNG trial received a total of four scans 
(Becker et al., 2015; Infante et al., 2015; Pegna et al., 2013; Saghir et al., 2012). 
 The eight cohort studies had sample sizes that ranged from 1,000 to 7,915 (Horeweg et 
al., 2014; Roberts et al., 2007).  The number of computed tomography (CT) scans performed 
varied.  Participants in Greenberg et al.’s (2012) study and Veronesi et al.’s (2013) study 
received up to 10 CT scans.  Participants in Veronesi et al.’s (2014) and Menezes et al.’s (2010) 
studies received up to five annual LDCT scans, while three scans were performed in the 
NELSON trial (Horeweg et al., 2014).  A baseline scan and one annual scan were performed in 
Wilson et al.’s (2008) study.  Roberts et al. (2007) performed one single scan for their 
participants.  It is not clear how many scans each participant received in Dhopeshwarkar et al.’s 
(2011) study.  Participants in the majority of the studies in this integrative review received 
screenings annually, but some participants received scans biennially in Greenberg et al.’s (2012) 
study.  In the NELSON trial, Horeweg et al. (2014) performed scans with increasing screening 
intervals at one, two, and 2.5 years. 
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 All participants in these studies were current or former smokers aged 50 years and older 
with at least a 10 pack-year history of smoking.  Seven of the studies required that smokers had 
quit within the past 10 years (Gohagan et al., 2005; Horeweg et al., 2014; Infante et al., 2015; 
Saghir et al., 2012; Veronesi et al., 2013; Veronesi et al., 2014; Wilson et al., 2008).  The 
National Lung Screening Trial Research Team (2011) and Blanchon et al. (2007) included 
participants who had quit smoking within the past 15 years, while the remaining studies included 
all former smokers (Becker et al., 2015; Dhopeshwarkar et al., 2011; Greenberg et al., 2012; 
Menezes et al., 2010; Pegna et al., 2013; Roberts et al., 2007).  The studies in this review 
included healthy participants; some exclusion criteria included history of cancer (except non-
melanoma skin cancer), presence of a condition limiting life expectancy, recent chest CT scan, or 
participation in another lung screening study. 
Lung cancer mortality.  Results on lung cancer mortality were reported in three RCTs 
and two cohort studies (Infante et al., 2015; Saghir et al., 2012; The National Lung Screening 
Trial Research Team, 2011; Veronesi et al., 2013; Veronesi et al., 2014).  The National Lung 
Screening Trial Research Team (2011) reported a relative reduction in lung cancer mortality of 
20% with LDCT (95% CI, 6.8-26.7; p = .004); the rate of death from lung cancer in the LDCT 
group was 247 per 100,000 person-years and 309 per 100,000 person-years in the CXR group.  
Infante et al. (2015) and Saghir et al. (2012) found no statistically significant differences in 
mortality between screening groups.  In Saghir et al.’s (2012) study, there were 15 (0.73%) 
deaths from lung cancer in the LDCT group as compared to 11 (0.54%) in the control group (p = 
.428).  Infante et al. (2015) found a lung cancer mortality rate of 543 per 100,000 person-years in 
the LDCT arm versus 544 per 100,000 person-years in the control arm (hazard ratio, 0.993; 95% 
CI, 0.688-1.433).  Veronesi et al. (2014) reported that 28 of 136 deaths (20.59%) were due to 
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lung cancer.  Over the 10-year period, 23 deaths (38%) due to lung cancer occurred in Veronesi 
et al.’s (2013) study. 
All-cause mortality.  In four RCTs and two cohort studies, results were reported on all-
cause mortality (Becker et al., 2015; Infante et al., 2015; Saghir et al., 2012; The National Lung 
Screening Trial Research Team, 2011; Veronesi et al., 2013; Veronesi et al., 2014).  The 
National Lung Screening Trial Research Team (2011) found a statistically significant difference 
between all-cause mortality rates in the two groups which produced an overall mortality 
reduction with LDCT of 6.7% (95% CI, 1.2-13.6, p = .02); there were 1,877 deaths in the LDCT 
group and 2,000 deaths in the CXR group.  Notably, when excluding deaths from lung cancer in 
the comparison, the reduction in overall mortality with LDCT decreased to 3.2% and was no 
longer significant (p = .28) (The National Lung Screening Trial Research Team, 2011) .  Becker 
et al. (2015), Infante et al. (2015), and Saghir et al. (2012) did not find statistically significant 
differences in all-cause mortality rates between groups.  Veronesi et al. (2013) found 60 total 
deaths over a 10-year period, resulting in a mortality rate of 0.67 per 100 person-years; causes 
other than lung cancer included cardiovascular disease (17%), other cancer (20%), and other 
causes (25%).  Veronesi et al. (2014) reported 136 deaths. 
 Findings on mortality rates were only statistically significant in the NLST (The National 
Lung Screening Trial Research Team, 2011).  This is likely due to the large sample size in the 
NLST.  There was not enough power in the other studies to produce a statistically significant 
difference in mortality rates between groups.  But, there are other aspects of the studies to 
consider when comparing mortality rates.  The National Lung Screening Trial Research Team 
(2011) performed three annual scans, while there were five total scans in the other studies 
(Becker et al., 2015; Infante et al., 2015; Saghir et al., 2012; Veronesi et al., 2014).  Follow-up 
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times also varied between studies.  For the RCTs, Saghir et al. (2012) had the shortest median 
follow-up of 4.81 years, while Infante et al. (2015) had the longest median follow-up of 8.35 
years.  The National Lung Screening Trial Research Team (2011) followed participants for a 
median of 6.5 years, while Becker et al. (2015) followed participants for a range of three to 6.5 
years; follow-up is still being conducted in the LUSI trial.  An additional difference between 
studies is the criteria for inclusion; the studies differed between years since smoking cessation, as 
outlined above. 
Stage at diagnosis.  All of the studies in this integrative review contained reports of 
results on stage of lung cancer at diagnosis.  Of the RCTs, findings from three studies included 
statistically significant differences for stage at diagnosis of lung cancer between groups.  In the 
NLST, 63% of lung cancers were stage I in the LDCT group after a positive screening result as 
compared to 47.6% in the CXR group (The National Lung Screening Trial Research Team, 
2011).  Saghir et al. (2012) found that 70% of lung cancers diagnosed in the LDCT group were 
early stage (I-IIB) (48 of 69) as compared to 33% in the control group (8 of 33).  In the DANTE 
trial, there was a higher number of stage I lung cancers diagnosed in the LDCT group as 
compared to the control group (47 vs. 16, p = .0002) (Infante et al., 2015).  Gohagan et al.’s 
(2005) results did not produce a statistically significant difference in stage at diagnosis between 
groups; in the LDCT arm, 48% of lung cancers were stage I as compared to 40% in the CXR 
arm.  In the ITALUNG trial, 23 of 35 (66%) screen-detected lung cancers were stage I, while 42 
of 58 (72%) screen-detected lung cancers were stage I in the LUSI trial (Becker et al., 2015; 
Pegna et al., 2013).  Blanchon et al. (2007) found that three of eight (38%) LDCT-diagnosed 
lung cancers were stage I, while the only (100%) CXR-diagnosed lung cancer was stage I. 
The majority of lung cancers diagnosed by LDCT in the cohort studies were stage I.  
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Veronesi et al. (2013) reported that 55 of 71 (78%) LDCT-diagnosed lung cancers were stage I.  
Forty of 69 (58%) NSCLC cases were stage I in the Pittsburgh Lung Screening Study, and 44 of 
65 (68%) lung cancer cases were stage I in Menezes et al.’s (2010) study (Wilson et al., 2008).  
Of 81 NSCLCs diagnosed in Dhopeshwarkar et al.’s (2011) study, 55 were stage I (68%).  One 
hundred thirty-six of 175 (78%) lung cancer cases were stage I in Veronesi et al.’s (2014) study.  
Roberts et al. (2007) diagnosed 20 lung cancers by LDCT in their 1,000 participants (2%); 
nineteen were NSCLC, while one was SCLC.  Of the 19 NSCLC cases, 15 were stage I (78%) 
(Roberts et al., 2007).  Of 33 lung cancers diagnosed by LDCT in Greenberg et al.’s (2012) 
study, 26 (79%) were stage I. 
 Per these results, screening with LDCT results in detection of more lung cancers at an 
earlier stage; this leads to better prognosis for individuals diagnosed with lung cancer.  The 
National Lung Screening Trial Research Team (2011) found that screening with LDCT resulted 
in more diagnoses of lung cancer versus CXR, but Gohagan et al. (2005) did not produce these 
results.  Due to the smaller sample size in Gohagan et al.’s (2005) study, only 60 lung cancers 
were detected between both groups as compared to 2,001 lung cancers being diagnosed in the 
NLST (The National Lung Screening Trial Research Team, 2011).  Earlier stage diagnosis with 
LDCT screening in the majority of the studies in this integrative review demonstrates the 
usefulness of LDCT as a screening tool for lung cancer.  Improved rates of earlier stage 
diagnosis of lung cancer can subsequently reduce lung cancer mortality rates.  If screening for 
lung cancer with LDCT were implemented at a national level, about 18,000 lung cancer deaths 
could be prevented annually (Goulart & Ramsey, 2013).  Although importantly, these benefits 
need to be weighed against the unintended harms and adverse effects of screening for persons 
exposed to LDCT who did not have lung cancer.  This is possible if patients who meet USPSTF 
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eligibility criteria are routinely identified by their primary care providers, educated about lung 
cancer screening, referred for LDCT annually, and compliant with follow-up protocols. 
Education and Shared Decision-Making 
Although there are few studies that evaluate the effect of lung cancer screening with 
LDCT on lung cancer mortality and all-cause mortality, findings from the largest RCT, the 
NLST, were statistically significant; there was a 20% relative reduction in mortality from lung 
cancer when LDCT was used (The National Lung Screening Trial Research Team, 2011).  Other 
studies that evaluated mortality did not have these significant findings, but these trials had much 
smaller sample sizes as compared to the NLST (Becker et al., 2015: Infante et al., 2015; Saghir 
et al., 2012; Veronesi et al., 2014).  There were high rates of earlier stage diagnosis with LDCT 
in the majority of studies in this integrative review.  Based on these promising findings and poor 
survival rates with late stage diagnosis of lung cancer, the recommendations of the USPSTF for 
lung cancer screening with LDCT should be implemented. 
The USPSTF recommends annual lung cancer screening with LDCT in adults aged 55 to 
80 years with at least a 30 pack-year history of smoking; this includes current smokers and 
former smokers who have quit within the past 15 years (Moyer, 2014).  Screening should be 
discontinued when it has been 15 years since quit date, when the patient turns 81 years old, or 
when comorbidity is present that significantly reduces life expectancy or the ability to have lung 
surgery (Moyer, 2014).  For patients who meet these criteria, the provider should have a 
discussion with the patient regarding risks and benefits of screening with LDCT and form a 
shared decision.  The USPSTF’s recommendation for lung cancer screening with LDCT is a 
Grade B recommendation, indicating that “there is high certainty that the net benefit is moderate 
or there is moderate certainty that the net benefit is moderate to substantial” (USPSTF, 2016).  
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The USPSTF also supports adherence to standardized follow-up protocols; the National 
Comprehensive Cancer Network (2014) has established protocols for follow-up on LDCT lung 
cancer screening (Moyer, 2014). 
Screening for lung cancer is the first cancer screening modality that requires 
documentation of a shared decision-making visit for reimbursement by the CMS (Carter-Harris 
et al., 2016).  Shared decision-making is a process that occurs between the patient and provider 
where the patient’s values regarding medical decisions are considered, and the patient is the 
focus of care (Delbanco & Gerteis, 2015).  The USPSTF recommends that a thorough 
conversation regarding lung cancer screening advantages, limitations, known harms, and 
potential harms between the patient and provider occur prior to initiation of screening (Moyer, 
2014).  The CMS (2016) require more thorough criteria to be met for reimbursement during a 
shared decision-making visit that are detailed in Appendix A.  Whether these discussions are 
occurring consistently between patients and providers is not clear. 
According to Carter-Harris et al. (2016), their study was the first to provide an evaluation 
of whether current and former smokers were having discussions with their health care providers 
about lung cancer screening with LDCT.  Carter-Harris et al. (2016) compared the prevalence of 
lung cancer screening discussions prior to the release of USPSTF guidelines in 2012 to after the 
publication in 2014.  A sample of United States individuals who met criteria for lung cancer 
screening were surveyed in 2012 and 2014; of 746 surveyed participants in 2012, 17% reported 
that they had a discussion with their health care provider about lung cancer screening as 
compared to 10% of 795 surveyed participants in 2014 (Carter-Harris et al., 2016).  Participants 
who were current smokers, who had a family history of cancer, and who had health care 
coverage were more likely to report having discussions with their provider about screening.  This 
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survey occurred within one year of the publication of the USPSTF guidelines; it has been three 
years since these participants were surveyed, and it is likely that rates of discussions have 
increased, but it cannot be substantiated. 
Lung cancer screening differs from other cancer screenings because it is largely due to 
behavior; eighty percent of deaths due to lung cancer have been associated with tobacco smoking 
(ACS, 2016a).  There is a stigma attached to lung cancer as many individuals have labeled it a 
“smoker’s disease” and believe that individuals who develop lung cancer have a personal 
responsibility for their disease (American Lung Association, 2014).  Lung cancer has also been 
labeled an “invisible cancer” as the onset of symptoms is late, there are poor survival rates, and 
there is a lack of knowledge (American Lung Association, 2014).  In a 2012 survey, the 
American Lung Association (2014) found that perceived knowledge rates of lung cancer among 
the public were 9% knew very much, 50% knew something, 30% did not know very much, and 
11% knew nothing. 
In another survey of 338 individuals who met USPSTF criteria for lung cancer screening 
with LDCT, attitudes and perceptions about lung cancer were evaluated (Cataldo, 2016).  The 
majority of the sample (82.2%) was concerned about long-term health effects of tobacco 
smoking; 66% were worried about lung cancer while 75.4% were scared by the thought of lung 
cancer (Cataldo, 2016).  Although the majority of patients perceived concern about lung cancer, 
only 26.9% of the sample reported that a clinician told them they were at high-risk of developing 
lung cancer, and 52.1% believed themselves at risk of developing lung cancer (Cataldo, 2016).  
Over two-thirds of the sample had positive thoughts about LDCT including decreased risk of 
mortality and improved prognosis with early detection. 
Decision aids.  Patients and providers both require resources to facilitate this difficult 
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discussion about screening for lung cancer.  As LDCT for lung cancer screening is relatively new 
and has its risks, a shared decision is necessary and recommended by the USPSTF and CMS.  
Few decision aids have been created to assist patients and providers with opting to undergo lung 
cancer screening with LDCT.  Decision aids educate patients about their options and allow them 
to make their own informed decision.  Decision aids for patients “significantly improve 
knowledge, result in more accurate risk perceptions, help patients become more assured about 
their decisions, decrease passive participation in decision making, and result in decisions 
consistent with patients’ values” (Volk et al., 2014, p. 61).  One decision aid in the literature was 
designed to educate patients with a six-minute video at the eighth grade reading level that 
included content on lung cancer,  its risk factors, a patient undergoing a LDCT scan, and benefits 
and harms of screening (Volk et al., 2014).  Of the 52 participants who viewed the video, 78.8% 
reported that they were more interested in lung cancer screening, and knowledge regarding lung 
cancer increased from 25.5% pre-video to 74.8% post-video (p < .01).  The majority of 
participants reported that they were clear about what screening benefits mattered most and what 
harms mattered most (94.1% vs. 86.5%, respectively) (Volk et al., 2014). 
In contrast, Lau et al. (2015) used an online decision aid in a sample of current and 
former smokers aged 45 to 80 years old with no prior history of lung cancer and no chest CT 
scan within the past year.  The decision aid included content on benefits and harms of screening, 
false-positive rate, follow-up testing, over-diagnosis, and radiation exposure.  Sixty individuals 
were sampled between August 2014 and December 2014 using a pre-test and post-test design.  
Lau et al. (2015) found that knowledge regarding lung cancer increased overall after viewing the 
decision aid (p < .001), and the mean overall Decisional Conflict Scale scores decreased from 
46.33 to 15.08, indicating less conflict (p < .001).  Concordance scores increased from 14 
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(23.73%) pre-decision aid to 35 (59.32%) post-decision aid (p < .001); concordance was 
characterized by individuals who were eligible to be screened and preferred to get screened, and 
individuals who were not eligible to be screened preferred not to get screened.  Among 
individuals who were not eligible for screening, perceptions about lung cancer screening benefits 
decreased significantly, perceived screening harms increased, and those who would get screened 
if it were free decreased (p < .001).  In addition, 76% of the sample thought the information was 
balanced, and 82% reported that there was enough information to help them make a decision 
regarding screening. 
Lau et al.’s (2015) study was limited in that there was a small sample size and a lack of 
an explanation for why patients would choose not to get screened even it were free.  Based on 
the results, it could be assumed that those patients preferred not to get screened based on 
perceived harms and perceived benefits of screening as those numbers increased and decreased, 
respectively.  This study demonstrates the variation in perceptions of lung cancer screening with 
LDCT after viewing an educational video.  Lau et al.’s (2015) findings support the importance of 
using a decision aid and having a discussion between the patient and provider as each choice to 
be screened is individualized and based on the patient’s values and beliefs. 
As there are few evidence-based lung cancer screening decision aids available in the 
literature, it is difficult to determine what information should be included and how it should be 
presented.  The decision aid in Volk et al.’s (2014) study requires a television or computer and 
time to view the video, while Lau et al.’s (2015) study requires a computer and internet access to 
view the content.  It would be difficult to plan ahead for a visit like this and plan ahead for a 
discussion regarding lung cancer screening.  Lau et al. (2015) and Volk et al. (2014) both found 
that knowledge about lung cancer increased significantly after viewing the decision aid, and that 
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participants were better able to make a decision regarding lung cancer screening.  As CMS 
requires specific criteria and topics to be discussed prior to the initiation of screening with the 
use of a decision aid, one that would be feasible in primary care practice is necessary. 
A paper decision aid to guide these discussions and one that the patient can keep would 
be ideal to utilize in primary care.  All of the topics required by the CMS should be included in 
the decision aid.  The patient should be encouraged to ask questions during the visit to make an 
informed, shared decision with the provider.  Screening individuals who meet eligibility criteria 
in primary care and other established facilities with access to lung cancer screening and 
treatment centers is essential to reduce mortality from lung cancer.  Additional resources to assist 
the provider in educating and screening their patients at high risk for lung cancer would be 
beneficial.  Based on this integrative review of the literature regarding lung cancer screening and 
decision aids, a DNP project was created and implemented.  A lung cancer screening toolkit was 
created, including a paper decision aid, to assist providers in initiating discussions with high-risk 
current and former adult smokers regarding lung cancer screening. 
Theoretical Framework 
 Havelock’s (1976) Theory of Planned Change was utilized for this clinical project to 
guide provider change within a primary care practice (Appendix B).  The Theory of Planned 
Change was a modified form of Lewin’s (1951) Force Field Analysis Theory to best provide a 
framework for change in the work setting (White & Dudley-Brown, 2012).  White and Dudley-
Brown (2012) describe the model in their book, Translation of Evidence Into Nursing and Health 
Care Practice.  There are seven total steps that are necessary for change.  These steps include 
Care, Relate, Examine, Acquire, Try, Extend, and Review.  Stage Zero, Care, highlights the 
importance for the need for change.  For this project, evidence for lung cancer mortality statistics 
AN EDUCATIONAL TOOLKIT FOR LUNG CANCER SCREENING  22 
 
and high rates of late stage diagnosis indicated the need for change in clinical screening.  This 
problem was identified in the literature and indicated the need for 100% compliance with lung 
cancer screening.  During Stage One, Relate, a relationship was built; this was considered the 
pre-contemplation phase (Bright Hub Project Management, 2012).  A primary care practice in 
need of an educational intervention on lung cancer screening was identified, and a relationship 
was built with stakeholders, specifically the Medical Director and office manager. 
Stage Two, Examine, assessed and determined the need for change.  During this stage, 
the DNP student worked with stakeholders to assess current practice and the need for change.  
This was considered the contemplation phase; the relationship could have terminated at this stage 
if stakeholders did not desire change or see a need for change (Bright Hub Project Management, 
2012).  However, a lack of knowledge regarding lung cancer screening was identified, and the 
relationship continued.  During Stage Three, Acquire, resources for change were obtained.  This 
stage occurred when data from the integrative review and pre-implementation survey was 
analyzed and utilized for a lung cancer screening toolkit.  Stage Four, Try, included the selection 
of a solution for change.  For this project, a PowerPoint to educate providers on lung cancer 
screening and a decision aid and toolkit with resources were selected and created. 
During Stage Five, Extend, the change was implemented into routine, every day practice 
and accepted.  The DNP student educated primary care providers about lung cancer, lung cancer 
screening, the decision aid, and the toolkit.  Providers gave feedback to the DNP student by 
completing a survey to enhance the decision aid and toolkit.  Providers were asked to use the 
decision aid and toolkit in practice with patients.  Like other individuals, providers may be 
resistant to change; it is important to focus on this stage and ensure that providers are in 
agreement with the toolkit’s content and ease of use. 
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The final stage, Renew, was characterized by maintaining the change.  After being 
encouraged to use the toolkit and decision aid in practice over a two month period, providers 
were administered a final survey to address benefits and barriers to use of the decision aid and 
toolkit.  Providers were encouraged to maintain the change by incorporating the decision aid and 
toolkit into every day practice; the change agent, the DNP student, separated from the 
organization and allowed the primary care providers and stakeholders to sustain the change 
independently.  This theory included several steps and addressed multiple factors that were 
necessary for change to occur.  Change can be difficult to incorporate into practice and sustain.  
Following these steps by identifying the problem and need for change, in addition to ensuring 
that stakeholders are aware of the deficit and desire the change, enhances the likelihood of 
sustainability. 
Project Design and Methods 
This project was an educational intervention designed to translate evidence supporting 
the need for lung cancer screening with LDCT into clinical practice.  Providers were educated 
using a PowerPoint presentation that focused on increasing awareness and knowledge of lung 
cancer screening.  The PowerPoint included statistics and information on lung cancer, USPSTF 
guidelines, CMS requirements, literature review findings on LDCT, literature on decision aids 
for lung cancer, nodule management with the Lung CT Screening Reporting and Data System 
(Lung-RADS), primary care role, and presentation of the decision aid and toolkit. 
A paper decision aid was created for primary care providers to use with their patients to 
facilitate a discussion about lung cancer screening.  The decision aid included information about 
lung cancer and its statistics, the purpose of screening, importance of adhering to annual 
screening, eligibility, impact of comorbidities, benefits and risks of screening, follow-up 
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diagnostic testing, over-diagnosis, false positive rates, radiation risk, and smoking cessation.  
CMS requirements were incorporated into the decision aid as many of the individuals who meet 
USPSTF eligibility criteria for lung cancer screening are Medicare eligible.  It benefits the 
provider as CMS requirements are met, and benefits the patient as he/she is able to take the 
decision aid home as a reference. 
The toolkit included multiple varied resources for the provider about lung cancer 
screening.  Resources were included from verified organizations including the Agency for 
Healthcare Research and Quality, ACS, American College of Radiology, Centers for Disease 
Control and Prevention, CMS, Lung Cancer Alliance, and USPSTF.  The DNP student searched 
these websites and the internet for valuable information for the provider.  These resources 
included information about CMS requirements, organization recommendations, lung cancer 
screening program information, Lung-RADS, patient handouts, resources websites, and smoking 
cessation information.  The PowerPoint, decision aid, and toolkit are presented in Appendix C. 
Setting and Resources 
 The clinical settings for this project were two family practices in Waltham and Weston, 
Massachusetts, which were both located within Middlesex County.  Middlesex County has a 
primarily Caucasian population with 80.1% of the estimated 1,570,315 population being 
Caucasian (U.S. Census Bureau, 2015; U.S. Census Bureau, n.d.).  The majority of the 
population (96.3%) was estimated to have health insurance coverage; there was estimated to be 
81.6% with private health insurance, and 26.1% with public health insurance (U.S. Census 
Bureau, n.d.).  In 2012, there was an estimated smoking prevalence of 14.8% in females and 
16.9% in males (Institute for Health Metrics and Evaluation, 2015).  The patient population for 
this project was males and females aged 55 to 80 years old who were current smokers or former 
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smokers who quit within the past 15 years with at least a 30 pack-year history of smoking.  
These are the criteria that are recommended for lung cancer screening by the USPSTF. 
Description of the group, population, or community.  The provider population that 
was included in this clinical project consisted of primary care providers who cared for adults 
aged 55 to 80 years old who were at high-risk of developing lung cancer.  Participants included 
six physicians and two nurse practitioners.  All were Caucasian, and ages ranged between 30 and 
60 years.  Two were male, and six were female.  At these practices, nurse practitioners conducted 
sick and follow-up visits, as well as occasional wellness examinations. 
Facilitators and barriers.  Potential barriers and facilitators were assessed and 
reevaluated post-educational intervention by the DNP student.  For providers, potential barriers 
to utilizing the toolkit included provider resistance to change and current practice, time 
constraints, and lack of agreement with guidelines.  According to a study in North Carolina of 
providers’ knowledge of lung cancer screening guidelines, 53% knew less than three of the six 
components of screening, and 25% did not know any components (Barton, 2015).  Perceived 
barriers included harm from false-positives (83%), lack of awareness by patients (81%), lack of 
insurance coverage (80%), and patient cost (87%) (Barton, 2015).  As providers were 
implementing the guideline recommendations and using the toolkit, it was essential to get a 
thorough history from them regarding their concerns; this was assessed in the surveys, which is 
detailed in Appendix D.  Potential facilitators included provider belief that LDCT is effective, 
knowledge of USPSTF lung cancer screening guidelines, desire for improvement, and current 
practices of screening for smoking history in primary care. 
For patients, potential barriers to use of the decision aid included patient resistance, time 
constraints, and illiteracy.  Barriers to having a discussion regarding screening included fear of 
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having cancer, not wanting to know they have cancer, and patient values.  Facilitators to utilizing 
the decision aid included availability, ease of use, and patient willingness to take an 
informational packet.  Facilitators to patients having a discussion with their provider regarding 
screening included trust, perceived knowledge and expertise of the provider, and interest in 
getting screened. 
Barriers to receiving a LDCT scan included access to a CT scanner, the patient’s ability 
to travel to get a CT scan, concerns regarding additional testing, and lack of knowledge.  
Facilitators to obtaining a LDCT scan for lung cancer screening included presence of CT 
scanners within the hospital, radiologists who are trained and knowledgeable regarding 
interpretation of chest CT scans, and high rates of health insurance in Middlesex County (96.3%) 
(U.S. Census Bureau, n.d.).  Among a telephone survey of United States adults, 78.5% of current 
smokers and 81.4% of former smokers stated that they would agree to a CT scan if their doctor 
recommended it (Delmerico, Hyland, Celestino, Reid, & Cummings, 2014).  For those who 
responded no, the most common reasons were lack of insurance and not wanting to find out if 
they had cancer (Delmerico et al., 2014). 
Goals and Objectives 
Table 1 
Goals and Objectives 
 Goals  Objectives 
1 To increase knowledge of 
lung cancer screening with 
LDCT in primary care 
providers. 
 Providers will be educated regarding lung cancer 
screening guidelines and the literature basis; they will be 
provided with a decision aid and toolkit with educational 
resources. 
 Providers will report increased knowledge regarding lung 
cancer screening practices with LDCT after viewing the 
PowerPoint presentation and toolkit. 
 Providers will report an understanding of USPSTF and 
CMS eligibility criteria for lung cancer screening. 
 Providers will give feedback regarding the educational 
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content of the toolkit and provide areas for improvement. 
2 To improve ease of 
discussions regarding lung 
cancer screening between 
primary care providers and 
patients at high-risk of lung 
cancer. 
 
 Providers will be educated regarding the importance of 
having a discussion regarding screening with their patients 
at high-risk for lung cancer and encouraged to use the 
decision aid to guide discussions. 
 Providers will be educated regarding the importance of 
forming a shared decision regarding screening with the 
patient. 
 Providers will give feedback to the DNP student regarding 
benefits, barriers, and areas for improvement of the toolkit 
and how it can be used effectively in primary care. 
 Providers will report benefits, barriers, and areas for 
improvement of the decision aid and how it can be used 
effectively in primary care. 
3 To increase rates of 
discussions between patients 
and providers regarding lung 
cancer screening with 
LDCT. 
 Providers will be educated regarding the importance of 
lung cancer screening and encouraged to use the decision 
aid to have a discussion regarding screening with their 
patients at high-risk for developing lung cancer. 
 Providers will be educated regarding the importance of 
creating a shared decision regarding screening with the 
patient. 
 Providers will report how many times the decision aid was 
utilized with their patients to discuss lung cancer 
screening. 
 The number of referrals for lung cancer screening will be 
compared pre-educational intervention and two months 
post-educational intervention. 
4 To increase rates of referrals 
for LDCT for lung cancer 
screening in high-risk, 
eligible patients. 
 Providers will be educated regarding the importance of 
lung cancer screening and encouraged to refer their 
patients at high-risk of developing lung cancer to receive 
annual LDCT. 
 The number of referrals for lung cancer screening will be 
compared pre-educational intervention and two months 
post-educational intervention. 
5 To increase patient 
knowledge of lung cancer 
screening with LDCT. 
 Providers will be educated regarding the importance of 
discussing lung cancer screening with patients and the 
importance of forming a shared decision to receive annual 
LDCT. 
 Providers will report acceptability of the lung cancer 
screening decision aid by patients. 
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Implementation Summary: Presentation and Toolkit 
Based on research evidence and recommendations and requirements from the ACS, 
CMS, and USPSTF, a lung cancer screening decision aid and toolkit, intended for use by primary 
care providers, was created.  A toolkit was created for both primary care offices, with multiple 
copies of the decision aid provided.  Some providers split their time between the two locations, 
while other providers worked primarily at one location.  To evaluate the educational intervention 











Date Sent Out 11/06/2016 12/04/2016 03/07/2017 
Number of 
Participants  
8 of 8 5 of 8 6 of 8 
Number of 
Questions 
14 20 19 
Goals To identify frequency of 
referrals for lung cancer 
screening, current 
knowledge and practices 
regarding lung cancer 
screening guidelines, 
barriers to screening, 
and resources utilized. 
To obtain information 
on benefits, barriers, and 
areas for improvement 
of the PowerPoint, 
decision aid, and toolkit. 




To determine if the 
toolkit and decision aid 
were useful, if patients 
accepted the decision 
aid, and if awareness of 
lung cancer screening 
improved. 
 
To achieve goal one, to increase knowledge of lung cancer screening with LDCT in 
primary care providers, eight providers received education regarding screening.  Prior to the 
educational intervention, an assessment of current knowledge and practices was completed using 
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a survey and talking with the Medical Director and office manager.  After conducting the pre-
assessment, providers were educated with a PowerPoint presentation and provided with the 
decision aid and toolkit.  Time was allotted for questions and discussion between the DNP 
student and providers.  An immediate post-educational intervention survey was administered to 
determine if providers felt more knowledgeable about lung cancer screening, if the content was 
useful, and how the content could be improved.  All online surveys were sent to providers via 
email.  The surveys included statements with Likert-Scale responses, questions with numerical 
responses, and open-ended questions.  Findings from the immediate survey were reviewed by the 
DNP student, and the toolkit and decision aid were altered to reflect the suggestions of the 
providers. 
To achieve goal two, to improve ease of discussions regarding lung cancer screening 
between primary care providers and patients at high-risk of lung cancer, a decision aid and 
toolkit were created.  The decision aid was designed to be used as a guide during discussions 
about screening with patients at high-risk for developing lung cancer, while the toolkit was 
designed to be used as a resource for providers.  Providers were given the revised decision aid 
and toolkit, and encouraged to utilize them with patients at high-risk of developing lung cancer 
over a two-month period; this was the implementation phase.  Additionally, two months later, a 
final survey was administered to determine ease of discussions about screening and patient 
acceptability of the decision aid. 
To achieve goal three, to increase rates of discussions between patients and providers 
regarding lung cancer screening with LDCT, facilitators and barriers to having a discussion were 
assessed prior to the educational intervention.  After the educational intervention, providers were 
asked how the toolkit and decision aid could be improved; tailoring resources to the providers’ 
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needs could enhance knowledge and use.  The number of referrals for lung cancer screening 
were assessed at each survey and compared.  At the final survey, providers were asked how 
many times they used the decision aid and toolkit over the implementation period.  Benefits and 
barriers to their use were addressed at the immediate and two-month post-educational 
intervention surveys. 
To achieve goal four, to increase rates of referrals for LDCT for lung cancer screening in 
high-risk, eligible patients, providers were educated regarding the importance of screening and 
compliance with USPSTF guidelines, and encouraged to refer their eligible patients.  The final 
survey addressed frequency of use of the decision aid and toolkit, benefits and disadvantages, 
and areas for improvement.  The number of referrals for lung cancer screening were assessed at 
each survey and compared. 
To achieve goal five, to increase patient knowledge of lung cancer screening with LDCT, 
providers were educated on the importance of having a meaningful discussion and forming a 
shared decision with the patient regarding screening for lung cancer.  Providers were asked if 
they thought patients were receptive to the decision aid, and if they found the toolkit helpful to 
use with their patients.  Providers also reported barriers to use of the decision aid with patients at 
the two-month post-survey.  The survey design included numerical responses, statements with 
Likert-scale responses, and open-ended questions. 
Data Analysis 
Descriptive statistics were used to analyze the data.   All questions, except the final 
question, required responses; therefore, there were no questions with missing data.  For open-
ended questions, themes were identified.  Benefits, disadvantages, and barriers to use of the 
decision aid, PowerPoint, and toolkit were identified.  Frequency of referrals for lung cancer 
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screening and frequency of use of the decision aid and toolkit were quantified.  Data was entered 
into Excel and organized.  Survey results are presented in Appendix D. 
Results 
 Pre-implementation survey.  The first survey was used to identify frequency of referrals 
for lung cancer screening, current knowledge and practices regarding lung cancer screening 
guidelines, barriers to screening, and resources utilized.  All eight providers responded to this 
survey.  Four providers agreed that they were aware of lung cancer screening guidelines, and 
four providers strongly agreed.  Responses regarding awareness of CMS requirements for a 
shared decision-making visit for lung cancer screening varied; two of eight providers strongly 
agreed that they were aware of CMS requirements, two agreed, three were neutral, and one 
disagreed.  Furthermore, two of eight providers strongly agreed, five were neutral, and one 
disagreed that they met all of the required aspects for a shared decision-making visit with 
Medicare patients.  These results highlighted that there was a need for education regarding 
guidelines, specifically the CMS requirements.  All eight providers identified education that 
would be helpful regarding lung cancer and screening.  Responses included anything, a review of 
the guidelines, Medicare guidelines education, other, patient handout, presentation, statistics, tool 
on Epic, and videos. 
Referrals for lung cancer screening were low; no referrals were made within the past 
week of sending the survey, and only two providers reported making one to two referrals over 
the past month.  Seven of eight providers reported that they had missed referring a patient for 
LDCT.  Four of eight providers agreed that they find it easy to have discussions about lung 
cancer screening with patients, while four providers felt neutral.  Factors identified as 
contributing to patients not being referred for LDCT included time (3 of 8 providers), pack-year 
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history not documented (2 of 8), pack-year history not assessed during the visit (2 of 8), patient 
refusal (4 of 8), and other (2 of 8).  One provider identified other factors including a non-
compliant patient population with many unaddressed needs that were of a higher acuity, and 
difficulties with the Epic system being poorly designed and not providing adequate clinical care 
reminders. 
Barriers to referring patients for LDCT were categorized into patient barriers and system 
barriers; seven of eight providers reported that there were barriers to referral.  Patient barriers 
included health care literacy, lack of interest, patient acceptance, and the visit not being related to 
smoking.  System barriers included disregard of primary care physician’s time by administration 
and specialists, insurance coverage, lack of adequate clinical support, not having all information 
required to order a LDCT scan, and a poor Epic system.  Barriers to educating patients regarding 
lung cancer screening were assessed.  Seven of eight providers reported that there were barriers, 
with three providers identifying time as a barrier.  Other barriers included awareness, education 
materials that are easily accessible and easily understood, handouts, knowledge of the workup 
after a positive screen, and videos; one provider reported there were no barriers to education. 
Six of eight providers reported that there were resources that they have and use for lung 
cancer while two providers reported there were no resources.  Of the six providers who identified 
resources, these included DOT phrases, Dynamed, Google, handouts, the internet, Primary Care 
Office InSite (PCOI), smoking history, and UpToDate.  One provider reported that there were 
very little resources.  All eight providers identified resources that would be helpful; these 
included handouts, Lung Cancer Association algorithm, and printed guidelines.  Three providers 
felt that an improved Epic system would be helpful including smart phrases with all talking 
points, and follow-up questions to alert the provider to order the test if there is a positive 
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smoking history.  Finally, one provider reported that it would be helpful if pulmonologists had a 
more proactive approach with lung cancer screening to reduce the burden on primary care 
providers. 
Immediate post-educational intervention survey.  The second survey was administered 
four days after providers received the educational intervention.  Four of the eight providers were 
able to attend the presentation in person.  All providers were emailed the PowerPoint, asked to 
review it if they did not attend the presentation, and asked to complete the survey.  Five out of 
eight providers completed the second survey which was intended to obtain information on 
benefits, barriers, and areas for improvement of the PowerPoint, decision aid, and toolkit. 
The results indicated that only one provider made a referral for LDCT during the week 
prior to the survey, and two providers made between one and two referrals for LDCT during the 
month prior to the survey.  Four of five providers agreed that the PowerPoint was useful and 
would be beneficial to practice, while one provider strongly agreed.  Knowledge about lung 
cancer screening improved post-presentation; all five providers agreed that they felt more 
knowledgeable about lung cancer screening after viewing the PowerPoint. 
Five of five providers reported what they liked about the PowerPoint, while three of five 
providers reported how it could be improved.  Providers reported that the PowerPoint was brief, 
clear, concise, and detailed; others reported that it provided important information, statistics, and 
benefits and harms of screening.  Providers suggested that the PowerPoint could be improved by 
adding statistics including numbers needed to treat, numbers needed to harm, and biopsies and 
stress from incidental findings and benign pulmonary lesions; one provider thought that the 
presentation could have been more interactive and shorter.  Providers were emailed the number 
needed to treat and number needed to harm values, and this information was added to the toolkit. 
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All five providers felt that the decision aid would increase patient knowledge of lung 
cancer screening and was easy to read, but there were concerns about implementing it into 
practice.  Four providers agreed and one provider strongly agreed that the decision aid would 
increase patient knowledge of lung cancer screening and would allow the patient to make an 
informed decision about screening.  All five providers agreed that the decision aid was easy to 
read.  One provider strongly agreed, three agreed, and one felt neutral about the decision aid 
helping the provider discuss lung cancer screening with patients.  One provider strongly agreed, 
two agreed, and two felt neutral about the decision aid being easy to incorporate into practice.  
Five of five providers reported what they liked about the decision aid; providers liked that the 
decision aid was straightforward for patients, easy to read and understand, easy to use, and 
included good information.  Four of five providers did not feel that the decision aid needed to be 
improved; one provider thought that it could be more basic, include information for low literacy 
patients, and have pictures. 
Three of five providers were able to view the toolkit; of those three providers, all three 
agreed that content in the toolkit was useful and would be easy to incorporate into practice.  
Three providers reported what they liked about the toolkit.  One provider felt that the toolkit was 
a good resource, one provider liked its ease of use, and another provider reported that it 
contained information that was easy to read for the patient.  Of the three providers that viewed 
the toolkit, two felt that it did not need to be improved, while one provider felt that additional 
websites could be added. 
Two-month post-educational intervention survey.  The final survey was administered 
after the two-month implementation phase.  Six of eight providers completed the final survey 
which was designed to determine if the toolkit and decision aid were useful, if patients accepted 
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the decision aid, and if awareness of lung cancer screening improved.  Four providers agreed and 
two strongly agreed that they felt more aware of USPSTF guidelines.  Four providers felt more 
knowledgeable about lung cancer screening, while one provider strongly agreed, and one felt 
neutral.  No referrals for lung cancer screening were made over the week before the survey; over 
the month before the survey, one to two referrals were made by one provider. 
The decision aid was used by two out of six providers over the two-month 
implementation period.  Of the providers that used the decision aid, one strongly agreed and one 
felt neutral about the decision aid increasing patient knowledge of lung cancer and screening; 
these two providers agreed that the decision aid allowed the patient to make an informed 
decision about screening for lung cancer and that the decision aid was easy to read.  These two 
providers felt that their patients accepted the decision aid; one provider strongly agreed and one 
agreed that the decision aid helped them to discuss lung cancer screening with patients and that 
the decision aid was easy to incorporate into practice.  Of the providers that used the decision aid 
with patients, reported benefits included that it was something that the patient could take home 
and look at, and that the discussion was laid out.  Barriers included that it was time consuming 
and that it may be too burdensome for the patient to make the decision to be screened for lung 
cancer.  The remaining four providers answered questions about the decision aid, although they 
reported that they did not use it during the implementation period; their responses are detailed in 
Appendix D. 
Over the two-month implementation period, one provider reported that he/she used the 
toolkit two to three times, while five providers did not use the toolkit.  The provider that used the 
toolkit agreed that the toolkit was useful and was easy to incorporate into practice.  This provider 
reported that the toolkit directed the discussion, but a barrier to its use was that it was time 
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consuming.  The remaining five providers answered questions about the toolkit, although they 
reported that they did not use it during the implementation period; their responses are detailed in 
Appendix D. 
Discussion 
 All eight providers responded to the first survey, while five and six providers completed 
the immediate and two-month post-educational intervention surveys, respectively.  All responses 
were anonymous, and it is unknown if the same providers did not respond to the post-educational 
intervention surveys.  Referrals for lung cancer screening did not improve post-implementation.  
This may be due to the fact that over a short, two-month implementation period, providers did 
not see enough patients with a positive smoking history, or coordinate follow-up for this 
discussion within the time frame.  Over a longer period of time, it is hoped that more patients 
who meet USPSTF criteria will be identified, and more discussions and referrals for lung cancer 
screening will be made. 
 The first survey assisted the DNP student in identifying potential barriers to having 
discussions regarding lung cancer screening with patients and referring patients for LDCT.  
Patient refusal (4 of 8 providers) and time (3 of 8 providers) were the most frequently reported 
responses for why patients do not get referred for LDCT.  In addition to barriers being identified, 
a lack of education regarding CMS requirements and USPSTF guidelines was identified; this 
aided the DNP student in tailoring education and resources to the providers’ needs. 
 The second survey focused on benefits, disadvantages, and areas for improvement of the 
PowerPoint, decision aid, and toolkit.  The PowerPoint content was beneficial and useful and 
increased knowledge regarding lung cancer screening.  The decision aid was perceived well, but 
not all providers felt that it could be easily incorporated into practice.  At the final survey, the 
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decision aid was still perceived as beneficial due to the discussion being laid out and the patient 
being able to take the decision aid home, but time and patient burden with making the decision to 
be screened for lung cancer were barriers to its use.  Due to the length of the conversation 
regarding lung cancer screening, it would be beneficial for patients to be brought in for a follow-
up appointment to discuss screening to allow for adequate time and questions.  Although many 
patients still feel that their provider is correct and should make all the recommendations, health 
care has changed.  Patient-centered care is promoted, and the patient’s values and beliefs should 
be incorporated into the shared decision between the patient/family and provider.  The provider’s 
role is to educate and guide the patient to health and well-being.  Finally, with the risks 
associated with screening, it is important to thoroughly discuss risks versus benefits, consider 
comorbidities, and form a shared decision with the patient. 
 Although the majority of providers reported not using the Toolkit over the two-month 
implementation period, four providers agreed that the content was useful, while two providers 
were neutral; the one provider that used the toolkit in practice agreed that the content was useful.  
Its incorporation into practice may have been difficult; the number of providers that agreed that it 
would be easy to incorporate into practice remained stable from survey two to survey three; at 
survey three, the only provider that incorporated the toolkit in practice agreed that it was easy to 
do this.  Barriers to its use included patient receptiveness and time.  These themes remained 
constant throughout the surveys.  Conversations regarding screening for lung cancer need to 
occur, but finding the time and approach is difficult.  The educational intervention and 
presentation of the decision aid and toolkit created awareness and provided resources to the 
primary care providers.  With time, adequate resources, and increased awareness, providers can 
better identify patients who meet criteria, schedule a follow-up visit to discuss screening, and 
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refer eligible patients for LDCT. 
 This DNP project is difficult to compare to other studies in the literature.  A search of the 
literature did not identify any study incorporating and evaluating provider education regarding 
lung cancer screening.  There are studies that address provider perception of lung cancer 
screening guidelines, but education and resources to increase referral rates were not provided 
(Duong et al., 2017; Klabunde et al., 2010; Lewis et al., 2015).  Another study, discussed 
previously, compared rates of discussions about lung cancer screening before and after the 
release of the USPSTF guidelines in 2013; but, this study looked at the patient perspective only 
(Carter-Harris et al., 2016).  Finally, two studies evaluated the effectiveness of an online and 
video decision aid for lung cancer screening; again, this study looked at the patient perspective 
and was discussed previously (Lau et al., 2015; Volk et al. 2014). 
Limitations.  This project had its limitations. The sample size was small, and not all 
providers responded to all surveys.  A discrepancy was noted in the final survey.  Only two of six 
providers reported that they used the decision aid over the past two months, but three providers 
reported in a later question that they used the decision aid and their patients accepted the aid.  It 
is unclear if one provider did not respond appropriately to the first question, or if they misread 
the later question.  This could also be accounted for by the survey design, as most questions were 
required to be answered, and there was not an option “not applicable” in all questions.  The DNP 
student did not have any interaction with patients, and their thoughts regarding the decision aid 
were not elicited directly.  Obtaining their thoughts directly may determine how to best approach 
the discussion from a provider perspective.  Further research regarding the patient perspective is 
indicated. 
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 Ethics and Human Subjects Protection 
 The University Institutional Review Board (IRB) reviewed the project proposal and 
determined that it did not involve human subjects research; therefore, this project was exempt 
from further review.  This DNP project did not include any interaction with patients; the DNP 
student only interacted with primary care providers.  No patient health information was obtained 
or reviewed; the Health Insurance Portability and Accountability Act (HIPAA) of 1996 was 
maintained as patient health information was protected and maintained as private (Health and 
Human Services Department, 2013).  The Standards of Care for practice in a primary care office 
was utilized by the DNP student and primary care providers during this project.  The providers 
who completed the survey and offered information and feedback regarding the lung cancer 
screening toolkit remained anonymous and did not have their statements connected to their 
name.  The DNP student kept this information private and utilized it for the DNP project only.  
The IRB determination form is presented in Appendix E. 
Conclusion 
 Deaths due to lung cancer account for one out of four cancer deaths in the United States 
(ACS, 2016a).  Lung cancer screening with annual LDCT has been shown in the literature to 
reduce lung cancer mortality and all-cause mortality, and improve rates of early stage diagnosis 
of lung cancer.  In the NLST, the National Lung Screening Trial Research Team (2011) provided 
promising, statistically significant results including a relative reduction in lung cancer mortality 
of 20% with LDCT (95% CI, 6.8-26.7; p = .004) (The National Lung Screening Trial Research 
Team, 2011).  The USPSTF, among other organizations, supports the use of annual LDCT for 
high-risk current and former adult smokers and recommends shared decision-making between 
the patient and provider.  This DNP project was designed to improve rates of lung cancer 
AN EDUCATIONAL TOOLKIT FOR LUNG CANCER SCREENING  40 
 
screening and ultimately reduce lung cancer mortality rates by increasing provider and patient 
knowledge of lung cancer and screening.  The results indicate that the decision aid and toolkit 
may be beneficial to practice, but provider time and patient receptiveness were barriers to their 
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Appendix A 
Requirements for CMS 
For coverage of lung cancer screening with LDCT, the Medicare beneficiary must meet ALL of 
the following criteria:  
 Age 55-77 years old 
 No signs or symptoms of lung cancer 
 At least a 30 pack-year history of smoking 
 Current smoker or former smoker who quit within the past 15 years 
 Have an order for lung cancer screening that meets National Coverage Determination 
(NCD) requirements 
The order for lung cancer screening with LDCT must include ALL of the following information 
regarding the beneficiary: 
 Date of birth 
 Pack-year history of smoking 
 Smoking status; if a former smoker, the number of years since cessation 
 Lack of signs and symptoms concerning for lung cancer 
 The ordering provider’s National Provider Identifier (NPI) 
Before the LDCT scan occurs for lung cancer screening, a lung cancer screening counseling and 
shared decision-making visit must occur where the order is written; the following elements must 
be met and documented: 
 Must be furnished by a physician or qualified non-physician practitioner (Physician 
Assistant, Nurse Practitioner, Clinical Nurse Specialist) 
 Determination of beneficiary eligibility for screening include age, lack of signs or 
symptoms of lung cancer, pack-year history of smoking, and number of years since 
cessation, if a former smoker. 
 Shared decision-making, with the use of one or more decision aids, including benefits 
and harms of screening, follow-up diagnostic testing, over-diagnosis, false positive rate, 
and total radiation exposure must be included.  
 Counseling regarding the importance of adhering to annual lung cancer screening with 
LDCT, comorbidities impact, and ability/willingness to be diagnosed and treated 
 Counseling regarding the importance of smoking cessation for current and former 
smokers; if beneficiary is a current smoker, information is provided about smoking 
cessation interventions, if appropriate 
 The furnishing of a written order for LDCT for lung cancer screening, if appropriate 
The reading radiologist and the radiology imaging facility also have specific criteria that must be 
met. 
(Centers for Medicare and Medicaid Services, 2016) 
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Appendix B 
Havelock’s (1974) Theory of Planned Change 
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Appendix C 
Lung Cancer Screening Decision Aid, PowerPoint, and Toolkit 
Lung Cancer Screening Decision Aid 
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Lung Cancer Screening Toolkit 
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Appendix D 
Pre-Implementation Survey Results 




































4. I am aware of the Centers for Medicare and 
Medicaid Services (CMS) requirements for a 











5. I address all of the required aspects for a 









6. I find it easy to have discussions with patients 












 Noncompliant patient population with many unaddressed needs of much higher acuity. 
Epic also not capable of adequate clical care reminders not limiteed to Lung CA 
screening (ie say patient is a candidate despite adequate documentation by quit date that 
they aren't. A generally very poor clinical version of Epic waste time of clinicians making 
it harder to provide appropriate care. 
 dont have time to address screening guidelines at every visit 
 
9. What kind of resources do you have and use for lung cancer screening? 
a. Smoking hx 
b. Up to date, Dynamed, PCOI 
c. Internet 
d. Very little 
e. I google different resources each time. 
f. None that im aware of 
g. Dot phrases and handouts 
87% 
13% 
7. Do you ever miss a patient that should be 











Pack-year history not documented
Pack-year history not assessed during visit
Patient refusal
Other (please specify)
8. What factors contribute to a patient not being 
referred for LDCT? 
Responses: 8; multiple responses allowed 
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h. None 
10. What kind of resources would be helpful? 
a. If a pos smoking hx, follow up questions that then if certain number pos direct me 
to ordering test 
b. Lung Cancer Association algorithm 
c. Printed guidelines or website that would be easy to get to. 
d. Actual insurance coverage for this for each patient that is a candidate. More 
proactive approach by our pulmonologist to address this as PCPs are dumped on 
extensively w/I NWH. 
e. A pro and con tip sheet for the patient. 
f. handouts 
g. same as above 
h. A smart phrase with all talking points 
11. What education would be helpful regarding lung cancer and screening? 
a. Patient handout 
b. Videos, presentation 
c. A review of the guidelines. 
d. see other 
e. Anything 
f. medicare guidelines education 
g. percentages of diagnosed lung cancer from this screening 
h. Tool on epic 
12. What barriers are there to educating your patients regarding lung cancer screening? 
a. Awareness 
b. Handouts, videos 
c. Time and easily accessible and easily understood education materials. 
d. se other 
e. Visit time. 
f. understanding the work up afterwards should they get a positive screen 
g. time 
h. none 
13. What barriers are there to referring patients for screening? 
a. Often missed bc not there to discuss smoking 
b. Insurance coverage 
c. Not sure there are any. 
d. lack of adequate clinical support, inappropriate and poorly function Epic version 
adopted by Partners. Dumping by specialist. Lack of information about each 
individuals insurance coverage for this. General disregard of PCP's time by 
administration and many specialist. 
e. Not having all the info needed for ordering the CT. 
f. healthcare literacy 
g. patient acceptance 
h. Pts usually are not interested 
14. Please provide any additional comments. 
a. N/A 
b. No 
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c. I’m worried about the high false positive rate 
Immediate Post-Educational Intervention Survey 
















3. The content in the Lung Cancer Screening 









4. The content in the Lung Cancer Screening 













5. After viewing the PowerPoint, I feel more 









6. The Decision Aid will increase patient 









7. The Decision Aid will allow the patient to make 
























9. The Decision Aid will help me to discuss lung 
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14. What did you like about the PowerPoint? 
a. That it was a brief concise review of the topic and the screening tool. 
b. Important information 
c. Gave stats and benefits, harms of the screening 
d. All the detailed info 
e. Clear and concise 
15. How could the PowerPoint be improved? Is there any additional content that should be 
added? 
a. I think the one stat Dr D asked about number needed to harm would be good to 
add 
b. More interactive and shorter 
c. number needed to treat as well as number needed to harm (biopsies, stress, etc. 
from incidental findings as well as benign pulmonary lesions) 
d. No 
e. Not sure 
16. What did you like about the Decision Aid? 
a. Straightforward for patient use 
b. Good info on it 
c. easy to read and understand 
d. The ease of its use 
e. I think I got a copy of it. It will be easy to understand 
17. How could the Decision Aid be improved?  
a. NO specific feedback at this time 
b. Make more basic with info for low literacy and pictures 
c. n/a 
d. Not sure 
e. Not sure 
18. What did you like about the Toolkit? 
a. I did not review the tool kit yet 
b. Good resource 
c. ease of use 
d. Easy to read info for the patient 
e. Not sure I got this 
19. How could the Toolkit be improved? Are there other resources/information that should be 
included in the Toolkit? 
a. n/a since have not reviewed tool kit 
b. N/a 
c. no thoughts 
d. Maybe some additional websites 
e. Not sure 
20. Please provide any additional comments about the Decision Aid, Toolkit, and/or 
PowerPoint presentation. 
a. Great job 
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Two-Month Post-Educational Intervention Survey 














3. How many times did you use the Lung Cancer Screening Decision Aid with patients over 


















5. I am more aware of the USPSTF guidelines for 


























7. The Decision Aid increased patient knowledge 










8. The Decision Aid allowed the patient to make 























10. If you used the Decision Aid with patients, do 









11. The Decision Aid helped me to discuss lung 
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13.  Please discuss benefits to using the Decision Aid. 
a. Did not use the decision aid in the last 2months 
b. Potential ease of use. 
c. Efficient decision making for screening 
d. discussion is laid out 
e. Takes the guess work out of itp 
f. something the patient can take home and look at 
14.  Please discuss barriers to using the Decision Aid. 
a. DId not use the decision aid in the last 2 months 
b. Difficulty with bringing it up with a patient. 
c. N/A 
d. time consuming 
e. Time!! 
f. it may be over burdensome to some people, they may feel that the decision is then 
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17. Please discuss benefits to using the Toolkit. 
a. Did not use the Toolkit in the last 2 months 
b. Patients have an easy to understand piece of information about what could be a 
scary and confusing topic. 
c. Ease of accessibility to the data 
d. directs discussion 
e. More organized information 
f. did not use toolkit much 
18. Please discuss barriers to using the Toolkit. 
a. Did not use the Toolkit in the last 2 months 
b. Having the right patient to use it with. 
c. Pt receptiveness 
d. takes time 
e. Time 
f. n/a 
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Appendix E 
IRB Determination Form 
 
